Teva Files 2016 Annual Report on Form 20-F
16 February 2017 - 10:10AM
Business Wire
In accordance with Section 203.01 of the New York Stock
Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd.
(NYSE and TASE: TEVA) announced today that it has filed its 2016
Annual Report on Form 20-F with the U.S. Securities and Exchange
Commission. The Annual Report can be found on the company’s website
at www.tevapharm.com as well as on the SEC website at www.sec.gov.
In addition, security holders may request a hard copy of the Annual
Report, which includes the company’s complete audited financial
statements, free of charge. Requests can be made by contacting Teva
Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or
by phone at (215) 591-8912.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by approximately 200
million patients in 100 markets every day. Headquartered in Israel,
Teva is the world’s largest generic medicines producer, leveraging
its portfolio of more than 1,800 molecules to produce a wide range
of generic products in nearly every therapeutic area. In specialty
medicines, Teva has the world-leading innovative treatment for
multiple sclerosis as well as late-stage development programs for
other disorders of the central nervous system, including movement
disorders, migraine, pain and neurodegenerative conditions, as well
as a broad portfolio of respiratory products. Teva is leveraging
its generics and specialty capabilities in order to seek new ways
of addressing unmet patient needs by combining drug development
with devices, services and technologies. Teva's net revenues in
2016 were $21.9 billion. For more information, visit
www.tevapharm.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170215006382/en/
Teva Pharmaceutical Industries Ltd.IR:United StatesKevin C.
Mannix, 215-591-8912Ran Meir, 215-591-3033orIsraelTomer Amitai, 972
(3) 926-7656orPR:IsraelIris Beck Codner, 972 (3) 926-7687orUnited
StatesDenise Bradley, 215-591-8974
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2024 to May 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From May 2023 to May 2024